PR Newswire BiotechOriginal article
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II
RegulatoryBlue Light Cystoscopy SystemsPositive
AI Analysis
Summary
Photocure announced the FDA has published a proposed order to initiate reclassification of its Blue Light Cystoscopy Systems from Class III to Class II medical devices, a regulatory change that could streamline the approval pathway for similar future submissions.
Outcome Details
FDA published proposed order to initiate reclassification from Class III to Class II
Importance:7/10
Sentiment:
0.70
FDAreclassificationClass III to Class IIcystoscopic systemsregulatory
Related Companies
Read the original article
Published by PR Newswire Biotech on August 14, 2026 4:18 PM